- Home
- EYEN vs SCNI Comparison
EYEN vs SCNI Comparison
Compare EYEN & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- SCNI
- Stock Information
- Founded
- EYEN 2014
- SCNI 2003
- Country
- EYEN United States
- SCNI Israel
- Employees
- EYEN N/A
- SCNI N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EYEN Health Care
- SCNI Health Care
- Exchange
- EYEN Nasdaq
- SCNI Nasdaq
- Market Cap
- EYEN 2.9M
- SCNI 3.2M
- IPO Year
- EYEN 2018
- SCNI N/A
- Fundamental
- Price
- EYEN $15.82
- SCNI $2.27
- Analyst Decision
- EYEN Hold
- SCNI
- Analyst Count
- EYEN 4
- SCNI 0
- Target Price
- EYEN $2.00
- SCNI N/A
- AVG Volume (30 Days)
- EYEN 9.3M
- SCNI 1.1M
- Earning Date
- EYEN 08-11-2025
- SCNI 08-14-2025
- Dividend Yield
- EYEN N/A
- SCNI N/A
- EPS Growth
- EYEN N/A
- SCNI N/A
- EPS
- EYEN N/A
- SCNI N/A
- Revenue
- EYEN $67,063.00
- SCNI $658,000.00
- Revenue This Year
- EYEN $7,680.45
- SCNI N/A
- Revenue Next Year
- EYEN $315.38
- SCNI N/A
- P/E Ratio
- EYEN N/A
- SCNI N/A
- Revenue Growth
- EYEN 663.82
- SCNI N/A
- 52 Week Low
- EYEN $0.85
- SCNI $1.90
- 52 Week High
- EYEN $124.80
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- EYEN 77.71
- SCNI 44.70
- Support Level
- EYEN $7.50
- SCNI $2.14
- Resistance Level
- EYEN $14.33
- SCNI $2.85
- Average True Range (ATR)
- EYEN 2.92
- SCNI 0.20
- MACD
- EYEN 0.87
- SCNI 0.01
- Stochastic Oscillator
- EYEN 90.98
- SCNI 20.55
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.